08:33pm Sunday 18 November 2018

Experimental vaccine may reduce post-stroke blood clot risk

Study Highlights:

 

  • An experimental vaccine might one day protect ischemic stroke survivors from developing blood clots and subsequent strokes.
  • The vaccine was found to be as safe and effective as one of the most widely used oral blood thinners currently used to reduce clotting risk.

 

DALLAS  — A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood clots, without increasing the risk of serious bleeding or triggering an autoimmune response, according to new research in the American Heart Association’s journal Hypertension.

People who have had a stroke caused by a blood clot (ischemic strokes) often need to take medications that make their blood less likely to clot, which helps prevent another stroke.

Japanese researchers successfully tested an experimental vaccine in mice and found that it provided protection against blood clots for more than two months without increasing the risk of bleeding or causing an autoimmune response. The lack of an autoimmune response is important, because it means the mice’s immune system did not perceive the vaccine as an “intruder” that needed to be attacked, which would have caused a reaction to the vaccine.

The vaccine, S100A9, inhibits blood clot formation and, during the study, protected the arteries of treated mice from forming new clots for more than two months, and additionally, worked as well as the oral blood thinner clopidogrel in a major artery, according to Hironori Nakagami, M.D., Ph.D., study co-author and professor at Osaka University, in Japan.

Developing a vaccine to replace and/or compliment daily, oral medications might save many lives and help prevent both secondary strokes and possibly heart attacks, according to Nakagami.

“Many stroke patients don’t take their blood thinning drugs as prescribed, which makes it more likely they will have another stroke. This vaccine might one day help solve this issue since it would only need to be injected periodically,” Nakagami said.

“We are continuing our research in hopes of being able to start clinical trials between five and ten years from now, but there are differences between mice and humans in how the vaccine will be recognized by the immune system,” he said. “We should be able to overcome such problems and believe this vaccine provides a very promising strategy in secondary prevention of stroke.”

Co-authors are Tomohiro Kawano, M.D.; Munehisa Shimamura, M.D., Ph.D.; Tatsuya Iso, M.D., Ph.D.; Hiroshi Koriyama, M.D., Ph.D.; Shuko Takeda; Tsutomu Sasaki, M.D., Ph.D.; Manabu Sakaguchi, M.D., Ph.D.; Ryuichi Morishita, M.D., Ph.D.; and Hideki Mochizuki, M.D., Ph.D. Author disclosures are on the manuscript.

The Mochida Memorial Foundation for Medical and Pharmaceutical Research, the Japan Cardiovascular Research Foundation, and the Japan Agency for Medical Research and Development funded the study.

 

Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals. Foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.

 

The American Heart Association

 

 


Share on:
or:

Health news